SCHEMBL2837772

SCHEMBL2837772

CC(C)(C)OC(=O)NC(C(=O)c1ccc(OC2CCOCC2)nc1)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR3 Q99500 2/20 0.44
P2RX3 P56373 1/20 0.37
P2RX2 Q9UBL9 1/20 0.37
SCN9A Q15858 2/20 0.35
SCN5A Q14524 1/20 0.35
ACACB O00763 2/20 0.35
LRRK2 Q5S007 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
MAPK1 P28482 2/20 0.34
AAK1 Q2M2I8 1/20 0.34
TRPA1 O75762 1/20 0.34
DGAT1 O75907 1/20 0.34
AKT1 P31749 1/20 0.34
F10 P00742 1/20 0.34
PRSS1 P07477 1/20 0.34
PRSS2 P07478 1/20 0.34
F7 P08709 1/20 0.34
F3 P13726 1/20 0.34
PRSS3 P35030 1/20 0.34
SLC6A3 Q01959 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2834066 0.95 S1PR3 (0.43) S1PR3P2RX3P2RX2ACACBMAPK1
SCHEMBL2836299 0.88 S1PR3 (0.43) S1PR3P2RX3P2RX2SCN9ASCN5A
SCHEMBL2837373 0.87 S1PR3 (0.43) S1PR3P2RX3P2RX2ACACBLRRK2
SCHEMBL2837092 0.84 S1PR3 (0.42) S1PR3P2RX3P2RX2ACACBMAPK1
SCHEMBL2839740 0.84 S1PR3 (0.40) S1PR3P2RX3P2RX2ACACBMAPK1
SCHEMBL2836776 0.83 S1PR3 (0.46) S1PR3P2RX3P2RX2ACACBAAK1
SCHEMBL2836477 0.83 S1PR3 (0.39) S1PR3MAPK1AAK1TRPA1SLC6A3
SCHEMBL2836947 0.83 S1PR3 (0.40) S1PR3P2RX3P2RX2MAPK1AAK1
SCHEMBL2835006 0.82 S1PR3 (0.42) S1PR3P2RX3P2RX2MAPK1
SCHEMBL2832356 0.82 S1PR3 (0.42) S1PR3P2RX3P2RX2ACACBF10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367838-B2 Amines or amino alcohols as GLYT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-02-05 US disclosed
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS KOLCZEWSKI SABINE (DE) 2012-09-13 US disclosed
EP-2398558-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094659-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885P2RX3 3900/4885P2RX2 3551/4885
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885P2RX3 3900/4885P2RX2 3551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.